Innovent stock forecast
Innovent’s weighted forecast is HK$115.62 by October 2029. It hinges on durable product earnings, pipeline progress and cash conversion.
Where could Innovent’s shares be by 2029?
The weighted price is HK$92.90 in October 2027, a +4% return. It reaches HK$115.62 in October 2029, a +30% return. The probabilities are 35% bear, 50% base and 15% bull. The 2029 cases span HK$39.95 to HK$258.35 against today’s HK$89.05. Trailing P/E is 111.6x and next-twelve-month P/E is 35.0x.
| Case | Probability | October 2027 | October 2028 | October 2029 |
|---|---|---|---|---|
| Bear | 35 % | 30.73 (-65 %) | 35.05 (-61 %) | 39.95 (-55 %) |
| Base | 50 % | 100.25 (+13 %) | 112.31 (+26 %) | 125.77 (+41 %) |
| Bull | 15 % | 213.48 (+140 %) | 234.88 (+164 %) | 258.35 (+190 %) |
| Weighted | 100 % | 92.90 (+4 %) | 103.65 (+16 %) | 115.62 (+30 %) |
What has to go right, and what could go wrong for Innovent?
EBIT is the central operating assumption. The base case uses EBIT of RMB7,920m because revenue remains within management’s 2030 ambition and a 22% margin allows scale benefits without ignoring commercial and research costs. The bear case gives EBIT of RMB3,240m on slower uptake, price pressure and a 12% margin. The bull case gives EBIT of RMB12,600m on sustained mazdutide refills, global progress and a 28% margin. The 85.0% first-half gross margin supports operating leverage, but selling and marketing already cost RMB3,235.9m in that period.
How much cash does Innovent really make?
Free cash flow means operating cash after capital spending, lease payments and interest. Treating employee stock awards as an economic cost produces a stricter measure, because the awards dilute shareholders even though they are not cash payments. The table shows how dramatically the reported and stricter measures differ.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | 10,001.012 | 1,287.024 | 147.81 | -1,918.804 | -2,024.843 |
| − Capital spending | 269.88 | 965.665 | 1,119.385 | 896.896 | 1,065.634 |
| = Free cash flow | 9,623.834 | 172.969 | -1,130.987 | -2,948.322 | -3,193.023 |
| − Stock pay | 662.696 | 556.521 | 574.197 | 469.49 | 501.572 |
| = Real free cash flow | 8,961.138 | -383.552 | -1,705.184 | -3,417.812 | -3,694.595 |
What this means. The large 2025 cash increase is partly money received in advance for collaborations, so it is not all cash earned from sales this year.
What does an investor pay for Innovent today?
The P/E ratio compares a share price with earnings. A trailing P/E uses the last twelve months; a forward P/E uses forecast earnings for the next twelve months. The gap between Innovent’s two measures therefore assumes a rapid rise in profit. That is an expectation, not evidence that the shares are cheap.
| Today (Oct 19, 2026) | |
|---|---|
| Share price | 89.05 |
| P/E, last 12 months (calculated) | 111.6x |
| P/E, next 12 months (calculated) | 35.0x |
| Free cash flow yield (calculated) | 7.3% |
| Real free cash flow yield (calculated) | 6.8% |
| Dividend yield (calculated) | 0.0% |